Print

ACTG 326; PACTG 326

A Phase I/II Study to Evaluate the Safety and Immunogenicity of ALVAC HIV Vaccines Alone and with AIDSVAX B/B in Children Born to HIV-Infected Mothers

Trial Details:

I/II Completed
National Institute of Allergy and Infectious Diseases (NIAID) December 15, 1997
AIDSVAX B/B,ALVAC vCP1452 Protein env B; Canarypox gp120, TM gp41, gag, protease, nef, pol MN/LAI
ALVAC vCP1452 Viral Vector - Pox
AIDSVAX B/B Protein
USA 48
NCT00000879
http://clinicaltrials.gov/ct2/show/NCT00000879